Patents Assigned to Cyclacel Limited
-
Patent number: 6943026Abstract: Compositions for targeting expression of a gene such as an antitumor gene may contain a first nucleic acid construct in which expression of a first gene is controlled by a first promoter whose function is suppressed in non-tumor cells, and a second nucleic acid construct in which expression of a second gene for down-regulating the first gene in non-tumor cells is controlled by a second promoter that is up-regulated in non-tumor cells. The second promoter may be regulated by means of p53 binding, targeting expression of the first gene to cells in which p53 down-regulation of expression is disrupted, e.g. cells in which p53 is mutated. The first promoter may be one which is unregulated in tumor cells, for example the Hsp70 promoter which is upregulated in mutant p53 tumor cells. A suitable antitumor agent in thymidine kinase.Type: GrantFiled: October 2, 1996Date of Patent: September 13, 2005Assignee: Cyclacel LimitedInventors: Allan Balmain, Jing de Zhu
-
Publication number: 20050164976Abstract: A first aspect of the invention relates to a combination comprising a CDK inhibitor and 5-FU, or a prodrug thereof. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and 5-FU, or a prodrug thereof, as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a CDK inhibitor and 5-FU, or a prodrug thereof, to a subject.Type: ApplicationFiled: March 14, 2003Publication date: July 28, 2005Applicant: Cyclacel LimitedInventors: Simon Green, Ian Fleming, Rosemary Clarke, Steven McClue
-
Publication number: 20050153894Abstract: The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.Type: ApplicationFiled: April 13, 2004Publication date: July 14, 2005Applicant: Cyclacel LimitedInventors: Daniella Zheleva, Peter Fischer, Campbell Mclnnes, Martin Andrews, Weng Chan, Gail Atkinson
-
Publication number: 20050153991Abstract: The present invention relates to a method of treating a patient suffering from chronic lymphocytic leukemia (CLL) comprising administering a therapeutically effective amount of roscovitine or a pharmaceutically effective salt thereof.Type: ApplicationFiled: June 30, 2004Publication date: July 14, 2005Applicant: Cyclacel LimitedInventors: Athos Gianella-Borradori, David Lane, Paul Moss, Tatjana Stankovic, Simon Green
-
Patent number: 6828106Abstract: The present invention relates to a polypeptide multimer comprising a first polypeptide having associated therewith a label and a second polypeptide, wherein a) at least one of the polypeptides is susceptible to protease digestion; b) association of the polypeptides to form a multimer is detectable via a signal emitted by the label; and c) digestion of at least one polypeptide results in dissociation of the multimer and modulation of the signal emitted by the label, and The method of detecting or monitoring the activity of a protease enzyme based on such a multimer.Type: GrantFiled: January 26, 2000Date of Patent: December 7, 2004Assignee: Cyclacel LimitedInventors: John Colyer, Joanne Lightowler
-
Publication number: 20040176301Abstract: The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.Type: ApplicationFiled: May 19, 2003Publication date: September 9, 2004Applicant: Cyclacel LimitedInventors: Daniella I. Zheleva, Peter M. Fischer, Campbell McInnes, Martin J.I. Andrews, Weng C. Chan, Gail E. Atkinson
-
Patent number: 6699854Abstract: The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.Type: GrantFiled: December 20, 2002Date of Patent: March 2, 2004Assignee: Cyclacel LimitedInventors: Shudong Wang, Peter M. Fischer
-
Publication number: 20040029791Abstract: The present invention identifies substances having the property of binding to cyclin dependent kinase (cdk) comprising: (i) a peptide including amino acid residues 84 to 103 of full length p16 protein, or an active portion or derivative thereof; or (ii) a functional mimetic of the fragment. active portion or derivative; the substance excludes full length p16. p15. p18 and p19 proteins. These substances are useful in tumour suppression by inhibiting the phosphorylation of Rb protein. Also described herein is the resolution of the amino acid motifs responsible for binding cdks, an FLD motif. corresponding to amino acid residues 90 to 92 of full length p16 protein. and an LVVL motif, corresponding to amino acid residues 94 to 97 of full length p16 protein. The substances disclosed herein can be used in the treatment of hyperproliferative disorders and to screen and design molecules having the similar properties.Type: ApplicationFiled: November 1, 2002Publication date: February 12, 2004Applicant: Cyclacel LimitedInventors: Robin Fahraeus, David Philip Lane
-
Publication number: 20030229105Abstract: The present invention relates to the use of a compound of formula I 1Type: ApplicationFiled: May 21, 2002Publication date: December 11, 2003Applicant: Cyclacel LimitedInventor: Fatah Kashanchi
-
Patent number: 6613878Abstract: Fragments of Fen1 that interact with PCNA are disclosed, together with the use of such fragments or mimetics of Fen1 in methods of screening for compounds useful in treating disorders in which PCNA is implicated. In particular, substances which have the property of binding to PCNA are disclosed, said substances comprising: (i) a fragment of the Fen1 protein containing a peptide of 89 amino acids from the C-terminal region or an active portion thereof; or, (ii) a fragment of the Fen1 protein containing the sequence motif QGRLDxFF; or, (iii) a functional mimetic of said protein fragments; where “x” is preferably the selected form the amino acids S, D or G.Type: GrantFiled: July 31, 1998Date of Patent: September 2, 2003Assignee: Cyclacel LimitedInventors: Lynne S. Cox, David P. Lane, Emma Warbrick, David M. Glover
-
Publication number: 20030152945Abstract: Polynucleotides encoding a number of Drosophila gene products are provided. Polynucleotide probes derived from these nucleotide sequences, polypeptides encoded by the polynucleotides and antibodies that bind to the polypeptides are also provided.Type: ApplicationFiled: May 30, 2002Publication date: August 14, 2003Applicant: Cyclacel LimitedInventors: Peter Deak, David Moore Glover, Carol Midgley
-
Publication number: 20030149057Abstract: The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.Type: ApplicationFiled: December 20, 2002Publication date: August 7, 2003Applicant: Cyclacel LimitedInventors: Shudong Wang, Peter M. Fischer
-
Publication number: 20030119735Abstract: The present invention relates to a novel drug delivery system of use in the improved delivery of drug therapeutic agents into target cells. The system comprises a drug moiety linked to a carrier moiety wherein the carrier moiety comprises a homeobox peptide or a fragment or derivative thereof.Type: ApplicationFiled: July 31, 2002Publication date: June 26, 2003Applicant: Cyclacel Limited of United KingdomInventors: Peter M. Fischer, Shudong Wang, Nikolai Zhelev
-
Patent number: 6569833Abstract: The present disclosure identifies substances having the property of binding to cyclin dependent kinase (cdk) comprising: (i) a peptide including amino acid residue 84 to 103 of full length p16 protein, or an active portion or derivative thereof; or (ii) a functional mimetic of the fragment, active portion or derivative; the substance excludes full length p16, p15, p18 and p19 proteins. These substances are useful in tumor suppression by inhibiting the phosphorylation of Rb protein. Also described herein is the resolution of the amino acid motifs responsible for binding cdks, an FLD motif, corresponding to amino acid residues 90 to 92 of full length p16 protein, and an LVVL motif, corresponding to amino acid residues 94 to 97 of full length p16 protein. The substances disclosed herein can be used in the treatment of hyperproliferative disorders and to screen and design molecules having the similar properties.Type: GrantFiled: April 7, 1999Date of Patent: May 27, 2003Assignee: Cyclacel LimitedInventors: Robin Fahraeus, David Philip Lane
-
Patent number: 6531479Abstract: The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.Type: GrantFiled: March 29, 2001Date of Patent: March 11, 2003Assignee: Cyclacel LimitedInventors: Shudong Wang, Peter M. Fischer
-
Patent number: 6472507Abstract: The present invention relates to a novel drug delivery system of use in the improved delivery of drug therapeutic agents into target cells. The system comprises a drug moiety linked to a carrier moiety wherein the carrier moiety comprises a homeobox peptide or a fragment or derivative thereof.Type: GrantFiled: July 2, 1999Date of Patent: October 29, 2002Assignee: Cyclacel LimitedInventors: Peter M. Fischer, Shudong Wang, Nikolai Zhelev
-
Publication number: 20020098236Abstract: The invention relates to modified and truncated forms of the membrane transport vector penetratin. Such truncated forms include 7-mer peptides that may in themselves include further variation.Type: ApplicationFiled: May 11, 2001Publication date: July 25, 2002Applicant: Cyclacel LimitedInventors: Peter Martin Fischer, Nikolai Zhelev
-
Patent number: 6242201Abstract: Substances are disclosed which have the property of binding to PCNA, the substances comprising (i) a fragment of the p21WAF1 protein including residues 141 to 160 of the p21WAF1 amino acid sequence, or an active portion or derivative thereof; or (ii) functional mimetics of these protein fragments. In particular, the PCNA binding activity is shown to lie within the sequence motif OTSMTDFY, with the residues shown in bold being critical for PCNA binding, with those underlined being important. These substances are useful in the treatments of disorders in which PCNA is implicated, e.g. hyperproliferative disorders such as cancer and psoriasis, the substances binding to PCNA to inactivate it or functionally deplete its level. Also disclosed is the use of a yeast two hybrid screening technique for screening candidate peptides for binding to PCNA.Type: GrantFiled: August 22, 1997Date of Patent: June 5, 2001Assignee: Cyclacel LimitedInventors: David Philip Lane, Lynne Suzanne Cox, Emma Warbrick, David Moore Glover